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Abstract
Prior research strongly implicates gastric acid and bile acids, two major components of the 
gastroesophageal refluxate, in the development of Barrett’s esophagus (BE) and its pathogenesis. 
Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been shown to protect esophageal 
cells against oxidative stress induced by cytotoxic bile acids. We conducted a pilot clinical study to 
evaluate the clinical activity of UDCA in patients with BE. Twenty-nine BE patients received 
UDCA treatment at a daily dose of 13–15 mg/kg/day for six months. The clinical activity of 
UDCA was assessed by evaluating changes in gastric bile acid composition and markers of 
oxidative DNA damage (8-hydroxydeoxyguanosine, 8OHdG), cell proliferation (Ki67), and 
apoptosis (cleaved caspase 3, CC3) in BE epithelium. The bile acid concentrations in gastric fluid 
were measured by liquid chromatography-mass spectrometry. At baseline, UDCA (sum of 
unchanged and glycine/taurine conjugates) accounted for 18.2% of total gastric bile acids. Post 
UDCA intervention, UDCA increased significantly to account for 93.39% of total gastric bile 
acids (p<0.0001). The expression of markers of oxidative DNA damage, cell proliferation, and 
apoptosis was assessed in the BE biopsies by immunohistochemistry. The selected tissue 
biomarkers were unchanged after 6 months of UDCA intervention. We conclude that high dose 
UDCA supplementation for six months resulted in favorable changes in gastric bile acid 
composition but did not modulate selected markers of oxidative DNA damage, cell proliferation, 
and apoptosis in the BE epithelium.
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 Introduction
Barrett’s esophagus (BE) is a condition where normal squamous epithelium is replaced by 
metaplastic intestinal-like columnar epithelium containing goblet cells (intestinal metaplasia, 
IM). This lesion is linked to the development of esophageal adenocarcinoma, a cancer with 
poor prognosis, and a median survival of less than one year [1, 2].
Animal and human studies strongly implicate gastric acid and bile acids, two major 
components of the gastroesophageal refluxate, in the development of BE and its 
pathogenesis [3–5]. It has been shown that BE patients have higher acid and bile acid 
exposure in their esophagus than patients with erosive esophagitis or controls [4, 5]. 
Hydrophobic bile acids, such as deoxycholic acid (DCA), are thought to play a major role in 
the development of gastrointestinal malignancies [6]. In humans, the incidence of cancers of 
the laryngopharyngeal tract, esophagus, stomach, pancreas, small intestine (near the 
Ampulla of Vater) and colon are all positively associated with intestinal levels of 
hydrophobic bile acids [6]. Preclinical studies demonstrated that a combination of a 
cytotoxic bile acid cocktail and low pH induces oxidative stress and oxidative DNA damage 
in cultured esophageal cells and in BE biopsies ex vivo [7, 8]. Similarly, Huo et al. showed 
that DCA induces the production of reactive oxygen species in Barrett’s cells which causes 
DNA damage and induces activation of the NF-κB pathway to prevent apoptosis in Barrett’s 
cells [9].
Ursodeoxycholic acid (UDCA), the most hydrophilic of the bile acids, was shown to protect 
against bile acid and low pH induced oxidative stress and oxidative DNA damage and 
modulate expression of enzymes associated with protection against oxidative stress in 
cultured esophageal cells [10]. Furthermore, in a rat model of BE, treatment with a 
combination of UDCA and aspirin resulted in fewer esophageal adenocarcinomas [11]. Peng 
and colleagues [12] have recently shown that UDCA treatment (10 mg/kg) for 8 weeks 
increased the levels of two antioxidant enzymes (glutathione peroxidase 1 and catalase) in 
esophageal biopsies collected from patients with BE. The treatment also prevented DNA 
damage and NF-κB activation induced by esophageal DCA perfusion in patients with BE. 
However, it is unknown whether UDCA treatment will decrease the extent of DNA damage 
under physiological condition (i.e., without esophageal DCA perfusion).
UDCA is an attractive candidate for chemoprevention because of its long-term safety record. 
It has been used safely at the dose of 8–10 mg/kg/day in patients with gallstone disease in 
the U.S. since 1987 and later in patients with primary biliary cirrhosis (PBC) at the dose of 
13–15 mg/kg/day. In the clinical trial setting, it has demonstrated potential for risk reduction 
for colorectal cancer with a good safety profile. UDCA treatment at a dose of 8–10 
mg/kg/day for a mean of 32 months was associated with a statistically significant 39% 
reduction in recurrence of colorectal adenomas with high-grade dysplasia [13]. A study of 
52 patients with ulcerative colitis and primary sclerosing cholangitis showed that treatment 
with UDCA (at a dose of 13–15 mg/kg/day for a median duration of 42 months) 
significantly reduced the risk of colorectal dysplasia or cancer compared with placebo [14].
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We conducted a pilot clinical study to assess the clinical activity of UDCA in patients with 
BE. The central hypothesis to be tested in the clinical study is that supplementation with 
UDCA would alter bile acid composition in the refluxate and subsequently decrease 
oxidative DNA damage, and cell proliferation and increase apoptosis in the BE epithelium.
 Materials and Methods
 Study Design
The study was an open label, single-arm intervention trial conducted at the University of 
Arizona (UA), University of North Carolina (UNC), and Southern Arizona VA Health Care 
System (SAVAHCS). The study was approved by the Institutional Review Board at each 
institution. The study endpoints were changes in oxidative DNA damage (measured by 8-
hydroxydeoxyguanosine levels), cell proliferation (measured by Ki-67 expression), and 
apoptosis (measured by cleaved caspase 3) in the BE epithelium and changes in gastric bile 
acid composition.
 Study Drug
Ursodiol (300 mg) capsules were supplied by the National Cancer Institute, Division of 
Cancer Prevention. The initial supply was manufactured by CorePharma LLC for Rising 
Phamaceuticals. Following expiration of the initial supply in August 2010, the replacement 
supply for the remainder of the trial was manufactured by Watson Pharma Private Limited 
and distributed by Watson Pharma, Inc.. The study capsules were stored at room temperature 
and protected from environmental extremes.
 Study population
We recruited healthy women and men ≥ 18 years of age with a diagnosis of BE with 
histologically-confirmed intestinal metaplasia anywhere in the tubular esophagus either with 
≥ 2 cm of involvement or with a minimum of circumferential BE length of 1 cm. 
Participants were required to have normal liver and renal function. Study exclusion criteria 
included BE with high grade dysplasia or carcinoma, medical conditions which would make 
completing endoscopies or completing the trial difficult, use of other investigational agents 
within 1 month, use of NSAIDs for more than 5 days a month within 1 month (except low 
dose aspirin (81 mg QD)), history of allergic reactions attributed to UDCA, uncontrolled 
acute and chronic diseases, pregnant and breast feeding women, major upper GI surgery 
within 6 months, erosive esophagitis at baseline endoscopy, chemotherapy, radiotherapy, or 
cancer-related hormonal or immunotherapy within the last 18 months, current or planned use 
of anticoagulant drugs, or use of cyclosporine. Written informed consent was obtained from 
all participants.
 Study procedure
During the initial visit, consented study subjects underwent medical and surgical history 
evaluation and had a blood sample collected for complete blood count (CBC) and 
comprehensive metabolic panel (CMP). Following the initial eligibility evaluation, subjects 
underwent upper endoscopy with biopsies. Prior to any mucosal irrigation, gastric fluid was 
aspirated through the endoscope and collected. The circumferential and maximum extents of 
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metaplasia were determined using the Prague C&M criteria [15]. Systematic biopsies – one 
in each of four quadrants every 2 cm in the appropriate areas of the BE – were taken. These 
biopsies were processed for histopathology based on the institutional standards. One 
additional BE biopsy was collected close to the distal end of the BE segment and flash 
frozen.
Eligible subjects then initiated the six months of UDCA treatment at 13–15 mg/kg per day. 
Subjects returned to the clinic after three months of agent intervention to return unused pills 
for a pill count, receive a new supply of agents, have a blood sample collected for CBC/diff 
and CMP, and review the side effects with study staff. At the end of the six-month 
intervention, subjects returned to the clinic to return unused pills, have a blood samples 
collected for CBC/diff and CMP, review the side effects with study staff, and undergo the 
post-intervention endoscopy to obtain gastric fluid and biopsies of the BE as described for 
the baseline endoscopy.
Safety of UDCA intervention was assessed by reported adverse events and clinical labs. 
Adverse events were graded using NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0.
 Analysis of Bile Acid Concentrations in Gastric Fluid
Bile acid concentrations in the gastric fluid were analyzed by HPLC tandem mass 
spectrometry. Briefly, an aliquot of gastric fluid was mixed with the internal standards 
(deoxycholic acid-d4 and glycoursodeoxycholic acid-d4) and then alkalized with 1N NaOH. 
The mixture was extracted with hexane. The aqueous phase was collected and acidified with 
5N HCl and extracted with ethyl acetate. The organic layer was dried and reconstituted with 
10 mM ammonium acetate/methanol (50/50) and injected onto the LC-MS system. The 
chromatographic separation was achieved using a gradient system of methanol and 10 mM 
ammonium acetate on an Ultrasphere XL column. Mass spectrometry was run in negative 
ion mode using eletrospray ionization. Detection of five bile acids (UDCA, deoxycholic acid 
(DCA), cholic acid (CA), chenodeoxycholic acid (CDCA), and lithodeoxycholic acid 
(LCA)) and their respective glycine and taurine conjugates was achieved by multiple 
reaction monitoring.
 Immunohistochemistry (IHC) for Tissue Biomarkers
IHC assays were used to assess markers of cell proliferation (Ki67), apoptosis (cleaved 
caspase 3, CC3), and oxidative DNA damage (8-hydroxydeoxyguanosine, 8OHdG) in BE 
epithelium tissue sections. The Ki67 and CC3 IHC was performed on a Discovery XT 
Automated Immunostainer (VMSI - Ventana Medical Systems, Tucson, Arizona) using 
VMSI validated reagents, including deparaffinization, antigen retrieval with a borate-EDTA 
buffer, primary antibody staining, detection and amplification and hematoxylin 
counterstaining. A biotin-free DAB (diaminobenzidine) detection system was used for CC3 
and a biotinylated-streptavidin-HRP and DAB system was used for Ki67. For Ki67, mouse 
monoclonal antibody (clone: MIB-1, Dako) was diluted 1:100. Human tonsil carcinoma was 
used as a positive control. For CC3, anti-CC3 rabbit polyclonal antibody (Cell Signaling 
Technology #9661L) was diluted 1:8,000. Human tonsil carcinoma was used as a positive 
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control. The 8OHdG IHC was performed as described previously [8] with minor 
modifications. Briefly, the slides were baked at 65°C for 1 hr, followed by deparaffinization 
with xylene, isopropanol, and water. Slides were then treated with 10% H2O2, 4N HCl, 
0.1M borax, and 5% horse serum sequentially prior to incubating with the mouse 
monoclonal antibody for 8OHdG (QED Bioscience, #12501 (clone 15A3), diluted 1:1000)). 
Slides were then incubated with secondary biotinylated rabbit anti-mouse IgG antibody, 
Vectastain Elite ABC reagent, and DAB prior to counterstaining with hematoxylin. Human 
esophageal carcinoma and tonsil carcinoma were used as the positive controls. On the IHC 
slides, longitudinally sectioned crypts opening to the lumen were selected for scoring. The 
percent of nuclei stained positive for Ki67, CC3, and 8OHdG in the selected regions was 
quantified by Aperio Spectrum software and confirmed by a trained pathologist. Slides with 
fewer than 500 total nuclei in the selected regions were excluded for the statistical analysis. 
The marker expression from different segments was averaged for participants with tissue 
sections from multiple esophageal segments.
 Statistical Analysis
Descriptive statistics were calculated to summarize the demographic characteristics and 
disease characteristics at baseline and post-intervention. The primary endpoint was the effect 
of UDCA intervention on 8OHdG levels in BE epithelium. Signed rank test was performed 
to assess pre to post-intervention change in percentage of nuclei stained strongly and 
moderately for 8OHdG. The secondary endpoints were measurements of changes in gastric 
bile acid composition and Ki67 and CC3 expression. Signed rank test was performed to 
assess the change for each of the secondary endpoints. Spearman correlation coefficients 
were calculated to assess the relationship between changes in gastric bile acid composition 
and changes in 8OHdG, Ki67, and CC3, respectively.
 Results
The study opened to accrual in April 2010 and closed to accrual in November 2013. Eighty 
potentially eligible participants were consented, 39 from UA, 26 from UNC, and 15 from 
SAVAHCS. Forty-four consented individuals did not meet all the eligibility criteria. Thirty-
six met all eligibility criteria to initiate agent intervention; of these 29 completed agent 
intervention, 1 was taken off agent intervention due to grade 2 diarrhea, an AE probably 
related to the study agent, that did not resolve within the protocol specified timeframe, 3 
were taken off agent intervention due to AEs deemed unlikely to be related or not related to 
the study agent, and 3 withdrew consent. UDCA treatment was well tolerated in our study 
cohort. Twelve subjects experienced related grade 1 or grade 2 AEs, including diarrhea, 
constipation, bloating, flatulence, nausea, vomiting, burping, rash, joint pain, and 
stomachache.
The demographic and disease characteristics of participants who completed the intervention 
are summarized in Table 1. The average age was 62.5 ± 9.8 yrs. The average BMI from these 
participants was 28.3 ± 5.1 kg/m2. Eighty percent were male. The majority were White 
(97%) and 14% were Hispanic. Current smokers accounted for 10% of these participants. 
Fourteen percent had heavy or moderate alcohol intake. Twenty-eight of the 29 participants 
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who completed agent intervention were treated concomitantly with proton pump inhibitor 
(PPI). Twenty-three of the 28 participants who used PPI had been treated with PPI for more 
than six months prior to initiating the UDCA intervention. Twelve of the 29 participants who 
completed agent intervention were taking daily 81 mg aspirin (ASA).
For disease characteristics of participants that completed the intervention, the median length 
of circumferential involvement was 4.0 cm at baseline, 13 participants with length < 3 cm 
and 16 participants with length ≥ 3 cm. The median circumferential involvement was 3.8 cm 
post intervention, 16 participants with length < 3 cm, 13 participants with length ≥ 3 cm. 
The circumferential length decreased in 24% of participants, was unchanged in 62% of 
participants, and increased in 14% of participants. Biopsies from 69% of participants were 
not dysplastic at baseline whereas 31% of participants had at least one biopsy with low 
grade dysplasia. Post intervention, biopsies from 83% participants were not dysplastic and at 
least one biopsy from 14% and 3% of participants had low grade and high grade dysplasia, 
respectively. The pathology grade improved in 17% of participants but worsened in 7% of 
participants.
There were 28 participants with gastric fluid collected at both the baseline and end of study 
endoscopies for bile acid analysis. Due to the large variation in gastric bile acid 
concentrations, the individual bile acids were expressed as the percent of total bile acid 
concentrations in the gastric fluid. The sum of each individual bile acid and its respective 
glycine and taurine conjugates is summarized in Table 2. At baseline, UDCA, CDCA, DCA, 
CA, LCA and their respective glycine and taurine conjugates accounted for 18.2, 10.99, 
38.87, 16.94, and 0.66% of total gastric bile acids. Post intervention, UDCA and its glycine 
and taurine conjugates increased significantly to account for 93.39% of total gastric bile 
acids whereas the composition of the other bile acids decreased significantly. Glycine 
conjugates constituted the majority of each of the five bile acid groups in the gastric fluid. 
We performed exploratory stratified analysis on the gastric bile acid composition by PPI use 
(< 6 months vs. ≥ 6 months), ASA use (yes vs. no), smoking status (never smokers vs. 
current or former smokers), alcohol intake (no current intake vs. any current intake), 
baseline BE length (<3 cm vs. ≥ 3cm), change in BE length (shortened vs. no change or 
increased), baseline pathology grade (ND vs. LGD), and change in pathology grade 
(improved vs. no change or worsened). There was no difference in the baseline gastric bile 
acid composition in most of the stratified analysis (data not shown) except that baseline 
DCA and its glycine and taurine conjugates accounted for a higher fraction of total gastric 
bile acid in ASA users than that in non-users [median (interquartile range): 44.99 (29.51)% 
(n=12) vs. 15.71 (37.41)% (n=16), respectively, p = 0.04]. Post intervention, the DCA and 
its glycine and taurine conjugates composition was similar between the ASA users and non- 
users [median (interquartile range): 2.87 (2.75)% vs. 5.88 (15.35)%, respectively, p = 0.12]. 
The stratified analysis showed that the pre to post-intervention change in bile acid 
composition was different between the ASA users and non-users [median change 
(interquartile range) of UDCA/conjugates: +75.65 (17.93) vs. +54.5 (57.13), p = 0.04; DCA/
conjugates: −43.61 (44.61) vs. −8.43 (25.63), p < 0.05; and CA/conjugates: −15.69 (9.68) 
vs. −4.22 (12.12), p = 0.02]. LCA and its glycine and taurine conjugates accounted for a 
small fraction of the bile acid composition. Stratified analysis showed that those who did not 
currently consume alcohol had a larger fraction of LCA/conjugates than those who 
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consumed alcohol [median (interquartile range): 0.52 (1.01)% (n = 7) vs. 0.12 (0.25)% (n = 
20), respectively, p = 0.03]. Nevertheless, the stratified analysis will need to be interpreted 
with caution due to the small sample size and multiple comparisons.
The tissue biomarker data are summarized in Table 3. Adequate baseline and post-
intervention data on 8OHdG, Ki67, and CC3 expression were obtained from 25, 29, and 27 
participants, respectively. Due to the concern of non-specific 8OHdG staining, only the 
percent of strongly and moderately stained nuclei was used for the statistical analysis. The 
median (interquartile range) baseline 8OHdG expression was 39.90 (39.14)%. The median 
(interquartile range) baseline Ki67 and CC3 expression, assessed as positively stained 
nuclei, was 35.92 (13.95)% and 1.62 (2.86)%, respectively. The expression of these markers 
did not change following 6 months of UDCA intervention. We performed similar 
exploratory stratified analysis on the tissue biomarkers. There was no difference in the 
baseline and post-intervention tissue biomarker expression in the stratified analysis (data not 
shown).
Table 4 summarizes the correlation between changes in gastric bile acid composition and 
changes in tissue biomarker expression. The changes in tissue biomarker expression were 
not correlated with the changes in gastric bile acid composition.
 Discussion
Our single-arm pilot clinical study was designed to evaluate the clinical activity of UDCA in 
patients with BE. We evaluated the clinical activity of UDCA by assessing changes in gastric 
bile acid composition and markers of oxidative DNA damage, cell proliferation, and 
apoptosis in the BE epithelium because prior research suggested that these markers could be 
modulated with UDCA intervention [10, 12]. The study showed that supplementation with 
UDCA at a daily dose of 13–15 mg/kg/day for six months in patients with BE increased 
proportions of cytoprotective bile acids and decreased proportions of cytotoxic bile acids in 
the gastric fluid. Despite the favorable change in the bile acid composition, we did not 
observe any significant changes in markers of oxidative DNA damage, cell proliferation, and 
apoptosis in the BE epithelium.
In our study, all but one participant were treated with PPI for symptom control with most 
treated for more than 6 months prior to initiation of the UDCA intervention. The PPI 
treatment may have contributed to the lack of UDCA effects on tissue markers of oxidative 
DNA damage, cell proliferation, and apoptosis. In a multicenter prospective cohort study of 
540 patients with BE, PPI use was associated with a reduced risk of neoplastic progression 
[16]. High-dose PPI treatment in patients with BE that results in effective esophageal acid 
suppression has been shown to decrease the markers of cell proliferation and inflammation 
and increase apoptosis [17]. PPI treatment reduces the acidity and the volume of the 
refluxate, which may diminish the exposure of esophagus to cytotoxic bile acids [18]. 
Therefore, modulation of bile acid composition with the UDCA intervention may not result 
in any further improvement in histology and the selected tissue biomarkers. Furthermore, 
bile acids that are cytotoxic to the mucosa in an acidic environment may lose their damaging 
activity at neutral pH from PPI treatment. Bozikas et al. [19] evaluated the effect of six 
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months of UDCA (600 mg BID) intervention in nine Barrett’s patients treated with high 
dose PPI. Similarly, UDCA intervention did not lead to significant changes in histology and 
markers of proliferation, differentiation, and inflammation in this study with limited sample 
size.
An alternative explanation for the lack of change in the selected tissue biomarkers is that 
cytotoxic bile acid reflux may not a causative factor in the pathogenesis of progression in 
BE. It was recently demonstrated in an animal model that cytotoxic bile acids and not gastric 
acid were pathogenic in the development of Barrett’s-like metaplasia [20], however the 
progression to dysplasia may be caused by other, unknown factors. The development of BE 
results in a more durable epithelium that may be more resistant to insult by refluxate. Thus, 
UDCA treatment may be more effective to prevent the development of BE than to prevent 
the pathogenesis of BE.
It is important to note that the null findings in the tissue biomarkers from this single-arm 
pilot study will need to be interpreted with caution as the study is limited by the lack of a 
control arm and the small sample size. The study selected an intervention duration of 6 
months to coincide with the recommended interval for surveillance endoscopy for BE 
patients with low grade dysplasia at the time of the study protocol development. Based on 
prior research [10, 12], it was anticipated that 6 months of UDCA intervention would be 
sufficient to modulate the selected tissue biomarkers. It is not known whether the selected 
tissue biomarkers would be modulated with a longer intervention duration.
The tissue biomarkers employed in this study have been correlated with the histological 
grade of Barrett’s esophagus [21–24] and used as intermediate biomarkers to assess 
preventive interventions in BE patients [17, 19, 25, 26]. However, these markers have not 
been proven in large, well-designed study to predict the risk of development of high grade 
dysplasia or adenocarcinoma. Multiple studies have shown that esophageal adenocarcinomas 
have extensive chromosomal instability, high levels of chromosome copy-number 
alterations, and frequent catastrophic chromosomal events [27–30]. Li and colleagues 
showed that esophageal adenocarcinoma risk predicted by somatic chromosome alterations 
outperformed risk predicted by TP53 mutation, flow cytometric DNA content, and 
histopathologic diagnosis of dysplasia [31]. This line of research may offer unique 
opportunities to identify exposures that lead to the mutation signatures in esophageal 
adenocarcinoma to better develop preventive strategies to target mutagens leading to the 
genomic alterations.
We conclude that high dose supplementation with UDCA for six months in patients with 
Barrett’s esophagus increased proportions of cytoprotective bile acids and decreased 
proportions of cytotoxic bile acids in the gastric fluid. Despite of the favorable change in the 
bile acid composition in the gastric fluid, we did not observe any significant changes in 
markers of oxidative DNA damage, cell proliferation, and apoptosis in the BE epithelium. 
Given recent research describing genomic alterations that develop in esophageal 
adenocarcinoma, future studies may consider determining the effects of UDCA on genomic 
alterations, as well as the effect of combining with PPI use, to determine its roles in 
prevention of neoplastic progression.
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Table 1
Demographic and disease characteristics of participants who completed agent intervention (n = 29).
Variable
Age, yr (mean ± SD) 62.5 ± 9.8
BMI, kg/m2 (mean ± SD) 28.3 ± 5.1
Gender
male/female 23/6
Race
White/Multi-racial 28/1
Ethnicity
Non-Hispanic/Hispanic 25/4
Smoking History
Current/Former/Never 3/14/12
Alcohol Intake Heavy/Moderate/Low/Occasional/Former/Never 0/4/10/7/5/3
Length of circumferential involvement, cm, median (range)
 Baseline 4.0 (1–11)
 Post-intervention 3.8 (1–12)
Length of circumferential involvement, <3 cm / ≥ 3 cm
 Baseline 13/16
 Post-intervention 16/13
Change in circumferential length, decreased/no change/increased 7/18/4
Pathology grade, ND/LGD/HGD
 Baseline 20/9/0
 Post-intervention 24/4/1
Change in pathology grade, improved/no change/worsened 5/22/2
Abbreviations: ND: no dysplasia; LGD: low grade dysplasia; HGD: high grade dysplasia
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Table 2
Gastric bile acid composition at baseline and post-intervention (n = 28).
Baseline (% of total bile acid) Post-Intervention (% of total bile acid) P valueb
UDCA and glycine/taurine conjugates 18.2 (26.1)a 93.4 (31.7) <0.0001
CDCA and glycine/taurine conjugates 11.0 (10.2) 1.01 (3.90) <0.0001
DCA and glycine/taurine conjugates 38.9 (44.0) 4.18 (7.82) <0.01
CA and glycine/taurine conjugates 16.9 (18.9) 1.72 (7.21) <0.0001
LCA and glycine/taurine conjugates 0.66 (1.30) 0.17 (0.37) <0.001
a
median (interquartile range)
bderived from signed rank test
Abbreviations: UDCA: ursodeoxycholic acid; CDCA: chenodeoxycholic acid; DCA: deoxycholic acid; CA: cholic acid; LCA: lithocholic acid
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Table 3
Tissue biomarker expressiona.
Baseline (% positive) Post-Intervention (% positive) p valued
8OHdG (n = 25) 39.9 (39.1)b,c 34.9 (30.7) 0.52
Ki67 (n = 29) 35.9 (14.0)e 36.9 (18.3) 0.44
CC3 (n = 27) 1.62 (2.86)e 1.00 (2.11) 0.25
alongitudinally sectioned crypts opening to the lumen were selected for scoring. Slides with fewer than 500 total nuclei in the selected regions were 
excluded for the statistical analysis. The marker expression from different segments was averaged for participants with tissue sections from multiple 
esophageal segments.
b
median (interquartile range)
c% of strongly and moderately stained nuclei
dderived from signed rank test
e% of positively stained nuclei
Abbreviations: 8OHdG: 8-hydroxydeoxyguanosine; CC3: cleaved caspase 3
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Table 4
Spearman correlation coefficient between changes in gastric bile acid composition of changes in tissue 
biomarker expression.
Bile Acid 8OHdG (N=25) Ki67 (N=28) CC3 (N=26)
Total UDCA 0.04; p=0.85 0.01; p=0.94 0.29; p=0.15
Total CDCA −0.16; p=0.43 −0.20; p=0.31 0.24; p=0.24
Total DCA −0.14; p=0.49 −0.19; p=0.34 −0.09; p=0.65
Total CA 0.24; p=0.26 −0.04 p=0.28 −0.23; p=0.26
Total LCA −0.07; p=0.74 0.01; p=0.96 0.06; p=0.78
Abbreviations: UDCA: ursodeoxycholic acid; CDCA: chenodeoxycholic acid; DCA: deoxycholic acid; CA: cholic acid; LCA: lithocholic acid; 
8OHdG: 8-hydroxydeoxyguanosine; CC3: cleaved caspase 3
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